FLT3 and Thrombocytopenia: A review by Xu et al. demonstrated that FLT3 inhibitors improved outcomes in the induction/reinduction stage of FLT3(+) AML; however, adverse reactions including thrombocytopenia, neutropenia, anemia, cardiac abnormalities, dyspnea, and cough were observed [135].